Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01702207
Other study ID # ESTTEROD
Secondary ID
Status Completed
Phase Phase 4
First received September 27, 2012
Last updated January 4, 2018
Start date October 2012
Est. completion date December 2017

Study information

Verified date January 2018
Source University of Saskatchewan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Current standard prophylactic immunosuppression in renal transplantation includes tacrolimus, a calcineurin inhibitor, dosed twice daily. In Canada, oral tacrolimus has been available as a twice daily formulation marketed as Prograf® since 1997. It has recently become available in an extended release formulation called Advagraf®, which is dosed once daily. Advagraf® has been demonstrated to be therapeutically equivalent to Prograf® in the renal transplant maintenance population, and as a result it has been is approved as an alternative to the twice daily formulation in these patients. There is an evolving and expanding positive clinical experience with Advagraf® in kidney transplantation and it has shown to be preferred by many patients, due to the diminished dosing frequency. In clinical trials, Advagraf® has been shown to have other potential benefits over Prograf® such as less inter and intra-patient variability, improved cardiovascular profiles, and improved kidney function. Compared to Prograf®, Advagraf® also has a lower Cmin or 'trough' concentration as well as a lower Cmax or 'peak' concentration. The purpose of this study is to convert stabilized renal transplant patients currently receiving Prograf® to Advagraf®, to investigate these potential therapeutic benefits.

The Framingham Risk Score and the Reynold's Risk Score are currently recommended by the Canadian Cardiovascular Society (CCS) to predict 10-year cardiovascular risk in the general population. Surrogate markers are widely used in clinical trials to shorten follow-up durations. In this study, the investigators will use the Framingham Risk Score and Reynold's Risk Score to quantify changes in estimated cardiovascular risk. The investigators also intend to examine novel inflammatory markers to investigate cardiovascular risk.

The investigators hypothesize that the more consistent drug exposure and lower Cmax noted with Advagraf® will decrease Framingham Risk Score, Reynolds Risk score as well as markers of inflammation in kidney transplant recipients.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria:

- Kidney transplant patients currently stable on the twice-daily formulation and who are followed as outpatients.

- Stability is defined as change in serum creatinine of less than 10% over the last two months

- Age 18-74 years old

- At least six months after transplantation

- Lack of rejection within the last 12 weeks

- Serum creatinine less than 300 umol/L at enrolment

- Negative urine pregnancy test for female patients of childbearing potential

- Consent to the study

- Not included in a clinical trial within the last 90 days

Exclusion Criteria:

- Patients with other types of solid organ transplants

- Patients with any form of substance abuse or psychiatric disorder.

- Patients with acute or chronic diarrhea

- Patients receiving anti-lymphocyte treatment for rejection within the last six months

- Patients on cyclosporine and or not receiving a mycophenolate derivative.

- Patients with significant liver disease defined as having an elevated bilirubin by at least two times the upper value of the normal range

- Patients who have any unstable medical condition that could interfere with the study

- Patients with chronic viral infection with HIV, Hep C and HCV.

- Presence of any acute illness requiring admission to the hospital for the last 4 weeks

- Pregnancy

- Significant cardiovascular event such as MI, stroke or TIA within the last 12 weeks or uncontrolled hypertension.

- Immunosuppressant changes within the last month.

Study Design


Intervention

Drug:
Once Daily Tacrolimus
Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
Twice Daily Tacrolimus
Subjects are kept on Prograf® which is the Twice Daily Tacrolimus

Locations

Country Name City State
Canada St Paul's Hospital Saskatoon Saskatchewan

Sponsors (2)

Lead Sponsor Collaborator
University of Saskatchewan Astellas Pharma Canada, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Framingham risk scores and change in the Reynolds Risk Score. Visit 1, Visit 3 (12 months)
Secondary Comparison in GFR between the two groups. Visit 1, Visit 3 (12 months)
Secondary Effect of therapy on CV biomarkers, insulin resistance and lipid profile. CV biomarkers will be assessed by luminex and insulin resistance and lipid profile will be assessed by the Metabolic Syndrome Visit 1, Visit 3 (12 months)
Secondary To look at change in the glomerular filtration rate (GFR) over the duration of the study. Vist 1, Visit 3 (12 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)